Further experience with intravenous immunoglobulin in women with recurrent miscarriage and a poor prognosis

H. J.A. Carp*, V. Toder, E. Gazit, R. Ahiron, A. Torchinski, S. Mashiach, Y. Shoenfeld

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Problem: Women with three or more unexplained miscarriages have a 60% chance of a subsequent live birth. Intravenous immunoglobulin (IVIG) has not been conclusively shown to improve this prognosis. This study assessed the effect of IVIG in patients exposed to have a poor outcome if untreated, i.e. women with five or more abortions, who have aborted after paternal leukocyte immunization or who continue to abort despite expressing anti-paternal complement dependent antibody. Methods: Seventy-six women received IVIG in a dose of 400 mg/kg body weight, in one day (total 30-45 g) in the follicular phase of a cycle in which pregnancy was planned. A booster dose was administered when pregnancy was diagnosed. Their results were compared to an untreated control group of 74 women. Results: Thirty-five (49%) pregnancies in treated women have resulted in live births or passed their previous stages of abortion compared to 23 (31%) in control patients (P = 0.04). Conclusions: These figures indicate that IVIG may prevent further miscarriages in this poor prognosis population. These figures are especially significant considering the doubt concerning the efficacy of IVIG in patients with three miscarriages and therefore a relatively good prognosis.

Original languageEnglish
Pages (from-to)268-273
Number of pages6
JournalAmerican Journal of Reproductive Immunology
Issue number4
StatePublished - 2001


  • Habitual abortion
  • IVIG
  • Immunomodulation
  • Pregnancy loss
  • Recurrent miscarriage


Dive into the research topics of 'Further experience with intravenous immunoglobulin in women with recurrent miscarriage and a poor prognosis'. Together they form a unique fingerprint.

Cite this